Pregled bibliografske jedinice broj: 1273993
Clozapine-Induced Inflammation: What Psychiatrists Should Know?
Clozapine-Induced Inflammation: What Psychiatrists Should Know? // Psychiatria Danubina, 34(3) (2022), 427-428 (međunarodna recenzija, pismo uredniku, stručni)
CROSBI ID: 1273993 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Clozapine-Induced Inflammation: What Psychiatrists Should Know?
Autori
Šagud, Marina
Izvornik
Psychiatria Danubina (0353-5053) 34(3)
(2022);
427-428
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, stručni
Ključne riječi
No key words
Sažetak
Clozapine continues to stand out as the most effective drug in the treatment of schizophrenia. It remains the only drug approved for the treatment-resistant schizophrenia, which, unfortunately, affects up to a quarter of people even in the early stages of this disorder (Siskind et al. 2022), and also the only antipsychotic with antisuicidal effects (Forte et al. 2021). At the same time, clozapine has a number of safety considerations, which contribute to its substantial underutilization (Gurrera et al. 2022).
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
